(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Native Americans had dice and games of probability long before other cultures, study finds - 2Step by step instructions to Explore Assessment Ramifications of Disc Rates
- 3Vote in favor of your Favored kind of craftsmanship
- 4Nature's Treats: 10 Organic products That Lift Prosperity
- 5Virtual reality opens doors for older people to build closer connections in real life
- Northern lights chances rise for Christmas as space weather remains unsettled
- Vote in favor of your favored spot to peruse
- Manual for Famous Beverages 2024
- UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- Vote in favor of the juice that you love for its medical advantages!
- Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
- Putin says Russian forces will seize capital of Zaporizhzhya
- Opening Your True capacity: 12 Techniques for Personal growth
- NASA says Maven spacecraft that was orbiting Mars has gone silent
